Zacks Investment Research upgraded shares of Cempra Inc. (NASDAQ:CEMP) from a hold rating to a strong-buy rating in a research report released on Tuesday morning. The brokerage currently has $25.00 price target on the stock.
According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “
CEMP has been the topic of several other research reports. Raymond James Financial Inc. began coverage on shares of Cempra in a research note on Tuesday, September 13th. They issued an outperform rating and a $32.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of Cempra in a research report on Tuesday, July 12th. They issued an overweight rating and a $31.00 target price on the stock. Robert W. Baird reissued an outperform rating and issued a $33.00 target price on shares of Cempra in a research report on Tuesday, August 2nd. Needham & Company LLC reissued a buy rating and issued a $48.00 target price on shares of Cempra in a research report on Wednesday, August 3rd. Finally, WBB Securities reissued a buy rating and issued a $40.00 target price on shares of Cempra in a research report on Tuesday, July 5th. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $36.08.
Shares of Cempra (NASDAQ:CEMP) opened at 21.62 on Tuesday. The stock has a 50 day moving average of $23.24 and a 200 day moving average of $19.72. The firm’s market cap is $1.12 billion. Cempra has a 52-week low of $14.03 and a 52-week high of $34.24.
Cempra (NASDAQ:CEMP) last announced its quarterly earnings data on Monday, August 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.16. The company had revenue of $3.42 million for the quarter, compared to analysts’ expectations of $3.89 million. Cempra had a negative net margin of 715.34% and a negative return on equity of 63.54%. The business’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.57) EPS. Equities analysts predict that Cempra will post ($2.63) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of CEMP. Johnson Investment Counsel Inc. boosted its stake in Cempra by 1.0% in the second quarter. Johnson Investment Counsel Inc. now owns 19,590 shares of the company’s stock worth $323,000 after buying an additional 200 shares during the period. Legal & General Group Plc boosted its stake in Cempra by 5.8% in the second quarter. Legal & General Group Plc now owns 7,102 shares of the company’s stock worth $117,000 after buying an additional 391 shares during the period. Quantitative Investment Management LLC boosted its stake in Cempra by 3.8% in the second quarter. Quantitative Investment Management LLC now owns 16,300 shares of the company’s stock worth $268,000 after buying an additional 600 shares during the period. ProShare Advisors LLC boosted its stake in Cempra by 2.5% in the second quarter. ProShare Advisors LLC now owns 40,947 shares of the company’s stock worth $675,000 after buying an additional 986 shares during the period. Finally, Kopp Investment Advisors LLC boosted its stake in Cempra by 1.1% in the second quarter. Kopp Investment Advisors LLC now owns 103,515 shares of the company’s stock worth $1,707,000 after buying an additional 1,104 shares during the period. Hedge funds and other institutional investors own 78.31% of the company’s stock.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.